NEWS

17 June 2010

ADial Pharmaceuticals attends 46th Annual DIA Meeting

http://www.diahome.org/diahome/FlagshipMeetings/home.aspx?meetingid=20751

 

06 May 2010

ADial Pharmaceuticals attends BIO International Convention

http://convention.bio.org/content.aspx?id=3012

 

03 March 2010

ADial Pharmaceuticals selected to present at the Second Annual UVa Venture Summit - Mar 25-26, 2010

http://www.virginia.edu/vpr/venture_summit.html

 

 

CORPORATE INFORMATION

Headquartered in Virginia, ADial Pharmaceuticals is focused on developing medicines to treat alcoholism, substance abuse, and addictive behaviors. With estimated costs of alcohol treatment and prevention at $7.5 billion annually, and only 1% spent on prescription medications, there is a sizeable opportunity for a 4-5 year investment in ADial Pharmaceuticals that should realize a significant return.

With secure patents, a highly qualified management team, unique medicines under development, and a clearly defined market opportunity, ADial is seeking venture capital or pharmaceutical partnership in an effort to progress our upcoming phase III clinical trial of a proprietary medication currently in development for alcohol dependence and abuse.

Parties interested in investment opportunities should contact:
Michael Keens
3445 Seminole Trail – Suite 103
Charlottesville, VA 22911
(434) 249-5225
email: mkeens@adialpharma.com